Natco Pharma Q1 internet declines 28% to 480 cr on pricing stress in U.S.

Generic drugmaker Natco Pharma reported consolidated internet revenue for the June quarter declined greater than 28% to ₹480.3 crore in comparison with ₹668.5 crore a 12 months earlier amid pricing stress in the important thing U.S. market and better analysis and growth expenditure.

The decrease internet revenue got here on a complete income that dipped 1.42% to ₹1,390.6 crore (₹1,410.7 crore). During the quarter the enterprise confronted pricing stress within the U.S. product portfolio and the corporate incurred elevated R&D bills on account of excessive worth tasks, Natco Pharma stated.

₹2 interim dividend

The firm has declared an interim dividend of ₹2 per fairness share (of ₹2 every) for the primary quarter.

Segmental income breakup confirmed formulations export declined, within the first quarter, to ₹1,126.5 crore (₹1,210.1 crore). Revenue from lively pharmaceutical components (API) elevated to ₹52.6 crore (₹39.2 crore), whereas that from home formulations to ₹107 crore (₹102.2 crore). Crop Health Sciences income elevated to ₹34.7 crore (₹15.6 crore).